Navigation Links
Nile Therapeutics Reports 2012 Second Quarter Financial Results
Date:8/14/2012

SAN FRANCISCO, Aug. 14, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX.PK), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its second quarter financial results for 2012. 

For the second quarter of 2012, Nile reported a net operating loss of $0.3 million, or $0.01 per share, compared to a net loss of approximately $0.9 million, or $0.03 per share during the second quarter of 2011. Weighted-average shares outstanding for the quarter were 43 million.

Net cash used in operating activities in the second quarter of 2012 was approximately $0.9 million. As of June 30, 2012, Nile had cash and cash equivalents of $0.8 million compared to $1.0 million as of December 31, 2011.About Nile TherapeuticsNile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting and the anticipated benefits of cenderitide for patients in the post-acute setting are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's immediate need to raise additional capital to fund its general corporate activities and its need to raise substantial additional capital to fund its planned Phase 2 study of cenderitide and to otherwise fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission on April 2, 2012. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

 Condensed Statement of OperationsThree months ended June 30,Six months ended June 30,2012201120122011Income:Grant income

$
-$
-$
-$
-Collaboration income

-346,000195,500346,000Total income

-346,000195,500346,000Operating expenses:Research and development

332,450702,930797,8031,325,262General and administrative

441,970523,305941,9901,098,583Total operating expenses

774,4201,226,2351,739,7932,423,845Loss from operations

(774,420)(880,235)(1,544,293)(2,077,845)Other income (expense):Interest income

5961,0468403,032Interest expense

----Other income (expense)

420,890(1,341)418,640(1,509)Total other income (expense) 

421,486(295)419,4801,523Net loss

$  (352,934)$  (880,530)$ (1,124,813)$ (2,076,322)Basic and diluted loss per share

$
(0.01)$
(0.03)$
(0.03)$
(0.06)Weighted-average common shares outstanding

42,951,79135,091,65341,332,01134,882,947 Summary Balance Sheet(in thousands)June 30,  2012December 31, 2011Cash and cash equivalents $
777$   1,039Working Capital$
75$
769Stockholders' equity$
542$
831 


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
2. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
3. Echo Therapeutics Announces Second Quarter 2012 Financial Results
4. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
5. Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
8. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
9. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
10. Silence Therapeutics - Admission of Shares and Board Update
11. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 ... studies the current and future scenario of the global ... for rising opioid consumption. Severe chronic constipation is a ... resistance to traditional laxatives. Hence, novel targeted therapy has ... of OIC sufferers, launch of targeted medicines, and growing ...
(Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
(Date:1/19/2017)... Jan. 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... specializing in the treatment of non-melanoma skin cancers ... superficial radiation therapy, today announced that it will ... financial results on Thursday, February 2, 2017 after the ... a conference call with the investment community on Thursday, ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer ... futuristic vision of its owner and founder. As Oat is recognized globally as one ... he knows personally as he believes it is a move to sow the seed ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma office ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two multi-specialist ...
(Date:1/20/2017)... ... 20, 2017 , ... A new partnership between Goodwill® and Roadie, Inc. aims ... need, from clothes to couches to dressers and bicycles. Roadie — the national on-the-way ... nearest Goodwill donation center through February 28th. , “January is an exciting time ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... ... 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s ... clinical trial has been life-saving as she has been on the trial for ... was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year ...
Breaking Medicine News(10 mins):